Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Peng, Fang ^a   Xu, Zumin ^a,b   Wang, Jin ^a   Chen, Yuanyuan ^a   Li, Qiang ^c   Zuo, Yufang ^b   Chen, Jing ^d   Hu, Xiao ^a   Zhou, Qichao ^a   Wang, Yan ^a   Ma, Honglian ^a   Bao, Yong ^a   Chen, Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; PIGMENT EPITHELIUM DERIVED FACTOR; RECOMBINANT ENDOSTATIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ENDOSTAR PROTEIN; ENDOSTATIN; EYE PROTEIN; MMP14 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PERICYTE; PROTEIN EXPRESSION; RADIATION RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ADJUVANT THERAPY; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; METABOLISM; NASOPHARYNX TUMOR; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; RADIATION DOSE; TUMOR CELL LINE; VASCULARIZATION;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; BASEMENT MEMBRANE; CELL LINE, TUMOR; ENDOSTATINS; EYE PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; PERICYTES; RADIATION TOLERANCE; RADIOTHERAPY, ADJUVANT; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859501370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034646     Document Type: Article

References (43)

1. Folkman J, (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416.
2. Carmeliet P, Jain RK, (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
3. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Medicine 7: 987-989.
4. Ferrara N, Kerbel RS, (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974.
5. Brown JM, Giaccia AJ, (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Research 58: 1408-1416.
6. Brown JM, (1999) The hypoxic cell: A target for selective cancer therapy- Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Research 59: 5863-5870.
7. Brown JM, William WR, (2004) Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer 4: 437-447.
8. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
9. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563.
10. Fukumura D, Jain RK, (2007) Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74: 72-84.
11. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, et al. (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13: 3395-3402.
12. Jain RK, Tong RT, Munn LL, (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67: 2729-2735.
13. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, et al. (2010) Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76: 1537-1545.
14. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, et al. (2010) Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas. Clinical Cancer Research 16: 3618-3627.
15. Hedlund EM, Hosaka K, Zhong Z, Cao R, Cao Y, (2009) Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci U S A 106: 17505-17510.
16. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, et al. (2009) Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 4: e6539.
17. Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, et al. (2011) Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. European Journal of Cancer 47: 656-666.
18. Yang S, Wu J, Zuo Y, Tan L, Jia H, et al. (2010) ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma. Curr Cancer Drug Targets 10: 611-622.
19. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
20. Ling Y, Yang Y, Lu N, You QD, Wang S, et al. (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84.
21. Sun Y, Wang J, Liu Y, Song X, Zhang Y, et al. (2005) Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 23: 654S.
22. Sizhong Z, Xiukung G, Yi Z, (1983) Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 31: 587-590.
23. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, et al. (2006) Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232.
24. Chung YL, Lee YHW, Yen SH, Chi KH, (2000) A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: Implications for radiosensitization and EBV-targeted therapy. Clinical Cancer Research 6: 1452-1458.
25. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, et al. (2010) Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. Journal of Biological Chemistry 285: 4931-4940.
26. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, et al. (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117: 2766-2777.
27. Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, et al. (2004) PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6: 333-345.
28. Hardee M, Eapen R, Rabbani Z, Dreher M, Marks J, et al. (2009) Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu(+) tumors. Cancer Chemotherapy and Pharmacology 63: 219-228.
29. Zhou QY, Guo P, Gallo JM, (2008) Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clinical Cancer Research 14: 1540-1549.
30. Ohta M, Kawabata T, Yamamoto M, Tanaka T, Kikuchi H, et al. (2009) TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today 39: 1046-1053.
31. Taguchi E, Nakamura K, Miura T, Shibuya M, Isoe T, (2008) Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 99: 623-630.
32. Jain RK, Batchelor TT, Duda DG, Willett CG, (2008) pp. 261-276 Normalization of tumor vasculature and microenvironment- A potential mechanism of action of antiangiogenic therapies; Teicher BA, Ellis LM, Teicher BA, Ellis LM: Humana Press Inc.
33. Maione F, Molla F, Meda C, Latini R, Zentilin L, et al. (2009) Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 119: 3356-3372.
34. Lee NY, Zhang QE, Garden AS, Kim JJ, Pfister DG, et al. (2011) Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615. 2011 ASCO Annual Meeting 29: 5516.
35. Carmeliet P, Jain RK, (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10: 417-427.
36. Dvorak HF, (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
37. Ek ET, Dass CR, Choong PF, (2006) PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 12: 497-502.
38. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, et al. (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285: 245-248.
39. Gao G, Li Y, Gee S, Dudley A, Fant J, et al. (2002) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277: 9492-9497.
40. Page-McCaw A, Ewald AJ, Werb Z, (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8: 221-233.
41. Kessenbrock K, Plaks V, Werb Z, (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
42. Ni Q, Ji H, Zhao Z, Fan X, Xu C, (2009) Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol 614: 1-6.
43. Lu N, Ling Y, Gao Y, Chen Y, Mu R, et al. (2008) Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med (Maywood) 233: 1013-1020.